Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Softbank Group Corp.
BioCentury | Apr 1, 2022
Management Tracks
Reed, Maraganore to join Takeda’s board
Plus Merck’s Frazier joins Eikon as independent director, and updates from Transgene and Syapse
BioCentury | Aug 6, 2021
Finance
With blockbuster aspirations for low-cost drugs, EQRx finds public path via SPAC
Blank-check merger, PIPE bringing $1.8B to allow biopharma to scale quickly
BioCentury | May 3, 2021
Deals
With homegrown pipeline set to reach clinic, Roivant chooses Patient Square’s SPAC as vehicle to NASDAQ
A merger between Roivant and a SPAC sponsored by Patient Square will create a publicly traded umbrella company with $2.3 billion to put toward drug discovery, in-licensing and development, including
BioCentury | Apr 28, 2021
Product Development
April 27 Quick Takes: Merck, Gilead move to expand access to COVID-19 antivirals; plus Exscientia-Softbank, Lilly, Aldeyra, LogicBio, Canbridge, Daiichi, Ultivue, Provention
Initiatives by Merck & Co. Inc. (NYSE:MRK) and Gilead Sciences Inc. (NASDAQ:GILD) will expand availability of the companies’ antivirals in India as the country’s COVID-19 crisis
BioCentury | Mar 30, 2021
Deals
March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest
SomaLogic Inc. is merging with CM Life Sciences II, a SPAC sponsored by Casdin Capital and Corvex Management (NASDAQ:CMIIU). The deal is expected to give the proteomics company up to $651 million
BioCentury | Feb 25, 2021
Finance
$135M series C buys Vividion flexibility to explore broad pipeline
Crossover investors, deals with Roche, BMS provide runway
BioCentury | Feb 11, 2021
Product Development
Feb. 10 Quick Takes: Softly goes PacBio; plus PGDx, Nuvation Bio, Gamida, Portal Innovations
Softbank Group Corp.’s SB Management unit is investing $900 million in Pacific Biosciences of California Inc. (NASDAQ:PACB) through the purchase of convertible senior notes due 2028. $103M
Items per page:
1 - 8 of 8